Close
  Indian J Med Microbiol
 

Figure 2: Preoperative immune cell subsets in patients with glioma and healthy subjects. Peripheral blood immune cells were collected from healthy people and glioma patients before surgery. The percentage of cells in immune cell subsets was calculated by flow cytometry. (A) Lymphocyte subsets: CD3+, CD4+, and CD4+/CD8+. (B) Immune cells: CD3− CD19+ B-lymphocytes, CD3− CD16+ CD56+ natural killer cells, and CD4+ CD25+ regulatory (Treg) cells. Data are expressed as the mean ± standard deviation (control group n = 40, glioma group n = 38). *P < 0.05, **P < 0.001, vs. control group;##P < 0.001, vs. CD3+;&P < 0.05,&&P < 0.001, vs. CD3-CD19+ B-lymphocytes (Student's t-test)

Figure 2: Preoperative immune cell subsets in patients with glioma and healthy subjects. Peripheral blood immune cells were collected from healthy people and glioma patients before surgery. The percentage of cells in immune cell subsets was calculated by flow cytometry. (A) Lymphocyte subsets: CD3+, CD4+, and CD4+/CD8+. (B) Immune cells: CD3− CD19+ B-lymphocytes, CD3− CD16+ CD56+ natural killer cells, and CD4+ CD25+ regulatory (Treg) cells. Data are expressed as the mean ± standard deviation (control group <i>n</i> = 40, glioma group <i>n</i> = 38). *<i>P</i> < 0.05, **<i>P</i> < 0.001, <i>vs</i>. control group;<sup>##</sup><i>P</i> < 0.001, <i>vs</i>. CD3+;<sup>&</sup><i>P</i> < 0.05,<sup>&&</sup><i>P</i> < 0.001, <i>vs</i>. CD3-CD19+ B-lymphocytes (Student's <i>t</i>-test)